18252 Federal Register / Vol. 77, No. 59 / Tuesday, March 27, 2012 / Notices 

influenza drug of the neurominadase 

inhibitor class, was recommended for 

treatment of and/or for prophylaxis in 

pregnant women during the 2009 H1N1 

influenza pandemic. In addition, two 

clinical studies conducted in pregnant 

women provide some pharmacokinetic 

data for oseltamivir. 

This workshop is open to all 

interested parties. The target audience 

includes professionals in the scientific 

community interested in discussing the 

challenges of evaluating medical 

countermeasures for effective and safe 

use during pregnancy. 

The workshop will include plenary 

and breakout sessions on the scientific 

challenges in the development of animal 

models of pregnancy that can be used to 

address the safety and efficacy of 

medical countermeasures. Broad topics 

to be covered in the plenary sessions 

include: (1) The physiology and 

pharmacology of pregnancy as it relates 

to model development; (2) the role of 

animal models in evaluating medical 

countermeasures, including influenza 

therapies, that may be used during 

pregnancy; and (3) experimental design 

considerations. Topics of the breakout 

sessions will include: (1) Animal model 

selection, (2) design of the 

pharmacokinetic studies, and (3) 

additional issues in experimental 

design. 

Background information on the public 

workshop, registration information, the 

agenda, and other relevant information 

will be posted, as it becomes available, 

on the registration Web site at http:// 

fda.contractmeetings.com. 

Transcripts: Please be advised that as 

soon as a transcript is available, it will 

be accessible at http:// 

www.regulations.gov. It may be viewed 

at the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD. A transcript will 

also be available in either hard copy or 

on CD–ROM, after submission of a 

Freedom of Information request. Send 

written requests to the Division of 

Freedom of Information (ELEM–1029), 

Food and Drug Administration, 12420 

Parklawn Dr., Element Bldg., Rockville, 

MD 20857. Send faxed requests to 301– 

827–9267. 

Dated: March 21, 2012. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2012–7290 Filed 3–26–12; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Environmental 

Health Sciences; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Environmental 

Health Sciences Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Environmental Health Sciences Council. 

Date: May 22–23, 2012. 

Open: May 22, 2012, 8:30 a.m. to 5 p.m. 

Agenda: Discussion of program policies 

and issues. 

Place: Nat. Inst. of Environmental Health 

Sciences, Building 101, Rodbell Auditorium, 

111 T.W. Alexander Drive, Research Triangle 

Park, NC 27709. 

Open: May 23, 2012, 8:30 a.m. to 9:30 a.m. 

Agenda: Discussion of program policies 

and issues. 

Place: Nat. Inst. of Environmental Health 

Sciences, Building 101, Rodbell Auditorium, 

111 T. W. Alexander Drive, Research 

Triangle Park, NC 27709. 

Closed: May 23, 2012, 9:45 a.m. to 12:30 

p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Nat. Inst. of Environmental Health 

Sciences, Building 101, Rodbell Auditorium, 

111 T.W. Alexander Drive, Research Triangle 

Park, NC 27709. 

Contact Person: Gwen W. Collman, Ph.D., 

Director, Division of Extramural Research & 

Training, National Institutes of Health, Nat. 

Inst. of Environmental Health Sciences, 615 

Davis Dr., KEY615/3112, Research Triangle 

Park, NC 27709, (919) 541–4980, 

collman@niehs.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.niehs.nih.gov/dert/c-agenda.htm, where 

an agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation—Health Risks from 

Environmental Exposures; 93.142, NIEHS 

Hazardous Waste Worker Health and Safety 

Training; 93.143, NIEHS Superfund 

Hazardous Substances—Basic Research and 

Education; 93.894, Resources and Manpower 

Development in the Environmental Health 

Sciences; 93.113, Biological Response to 

Environmental Health Hazards; 93.114, 

Applied Toxicological Research and Testing, 

National Institutes of Health, HHS) 

Dated: March 20, 2012. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–7333 Filed 3–26–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

NHLBI Conference Grants. 

Date: April 19–20, 2012. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Chang Sook Kim, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7179, Bethesda, MD 20892–7924, 301–435– 

0287, carolko@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Ancilliary Studies in Clinical Trials. 

mstockstill on DSK4VPTVN1PROD with NOTICES